Linking Muscle Dysfunction to Lung Disease: The Lundquist Institute Tackles COPD

Physical inactivity is best predictor of decline in COPD patients, US’ 4th-leading cause of death 

LOS ANGELES — Dr. Harry Rossiter, an investigator at The Lundquist Institute (formerly known as LA BioMed) was among the recipients of a $1.55 million grant award from the National Institutes of Health (NIH) to study muscle dysfunction in patients with chronic obstructive pulmonary disease (COPD), the fourth-leading cause of death in the United States.

Technologies First Created at The Lundquist Institute Achieve 3rd FDA Approval in 5 Years

Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.

LOS ANGELES — The U.S. Food and Drug Administration (FDA) approved Tepezza™ for the treatment of Thyroid Eye Disease (TED) on January 21, marking the fourth FDA-approved product containing technologies pioneered at The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), in the last 17 years—and the third in the last five years.